EXACT Sciences Corporation (EXAS)
EXACT Sciences Corporation Revenues: 1.036M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
EXAS Revenues Rankings
| Overall | 2nd percentile | 4311 of 4425 |
| Sector | 11th percentile | 414 of 470 in Healthcare |
| Industry | 20th percentile | 105 of 132 in Biotechnology |
EXAS Revenues Range, Past 5 Years
| Minimum | -0.663M | Sep 2008 |
| Maximum | 1.375M | Dec 2010 |
| Average | 0.7531M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these EXAS related companies
EXAS News
$EXAS http://stks.co/3jdc here is why I'm Loooong $EXAS. confident except for 'net profit margin'. Got any help for me there?
about 20 days ago by devlopr
about 20 days ago by devlopr
Listen to $EXAS Q1 2012 earnings call - live at 10:00 AM, ondemand after - http://stks.co/3bIX
about 28 days ago by earningscast
about 28 days ago by earningscast
Exact Sciences Corp (EXAS) Posts Wider than Expected Q1 Loss of 19c/Share
May 01, 7:37AM Street Insider
May 01, 7:37AM Street Insider
$EXAS filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3aWz
about 29 days ago by MarketBrief
about 29 days ago by MarketBrief
$EXAS forms bullish "Flag" chart pattern. http://stks.co/3JPa
about 47 days ago by RecogniaEvents
about 47 days ago by RecogniaEvents
NEW POST: "The Year the Market Overdosed on Biotechs" http://stks.co/37CC $AMLN $BMY $EXAS $IBB
about 62 days ago by chessNwine
about 62 days ago by chessNwine
Exact Sciences Corporation [EXAS] CEO to Ring The NASDAQ Stock Market Opening Bell
Mar 19, 11:04AM GlobeNewswire
Mar 19, 11:04AM GlobeNewswire
Exact Sciences’ Executives, Colon Cancer Challenge Leaders to Ring Nasdaq Opening Bell
Mar 19, 9:45AM Business Wire
Mar 19, 9:45AM Business Wire
Jefferies Boosts Price Target On Exact Sciences (EXAS) Following Q4, FDA Trial on Track
Feb 24, 12:13PM Street Insider
Feb 24, 12:13PM Street Insider
Auriga Reiterates a 'Buy' on Exact Sciences (EXAS); Raising PT After Q4 Review; Timelines on Track
Feb 24, 12:06PM Street Insider
Feb 24, 12:06PM Street Insider
Exact Sciences Corp (EXAS) Posts Q4 Loss of 18c/Share, Wider than Expected
Feb 23, 7:49AM Street Insider
Feb 23, 7:49AM Street Insider
Exact Sciences Reports Fourth-Quarter, Full-Year 2011 Financial Results
Feb 23, 7:30AM Business Wire
Feb 23, 7:30AM Business Wire
Exact Sciences Announces Appointment of Stoltenberg as Chief Commercial Officer
Feb 20, 4:25PM Business Wire
Feb 20, 4:25PM Business Wire
Exact Sciences (EXAS) Appoints Maneesh K. Arora as Chief Operating Officer
Feb 16, 4:48PM Street Insider
Feb 16, 4:48PM Street Insider
Exact Sciences to Host Fourth-Quarter and Full-Year 2011 Results Webcast and Call
Feb 16, 8:00AM Business Wire
Feb 16, 8:00AM Business Wire
Time for Exact Sciences Presentation at UBS Healthcare Services Conference Revised
Feb 06, 11:45AM Business Wire
Feb 06, 11:45AM Business Wire
Canaccord Genuity Initiates Coverage on Exact Sciences (NASDAQ:EXAS) - Video Summary Posted on www.InvestmentPitch.com
Jan 09, 6:23PM Thomson Reuters ONE
Jan 09, 6:23PM Thomson Reuters ONE
Canaccord Genuity Starts Exact Sciences (EXAS) at Buy; The Earlier The Better
Jan 06, 8:52AM Street Insider
Jan 06, 8:52AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| EXAS | 10.31 | +0.07 | +0.68% | 583.88M |
| EXAR | 8.00 | +0.09 | +1.14% | 355.16M |
| EXAM | 10.94 | +0.07 | +0.64% | 370.67M |
| EWZ | 53.27 | +1.13 | +2.17% | |
| EWX | 40.69 | +1.08 | +2.73% | |
| EWV | 39.25 | +0.47 | +1.21% | |
| EWU | 15.94 | +0.15 | +0.95% | |
| EWQ | 19.04 | +0.31 | +1.66% | |
| EWP | 22.14 | -0.75 | -3.28% | |
| EWO | 14.14 | +0.05 | +0.35% |
